Abstract
BACKGROUND: Percutaneous radiofrequency ablation (RFA) is a commonly used treatment for inoperable early-stage lung cancer, though it carries a significant risk of complications. Transbronchial RFA has emerged as a promising alternative, but robust clinical evidence supporting its adoption remains scarce. This study aims to investigate the safety and efficacy of transbronchial RFA in treating early-stage peripheral lung cancer. METHODS: This retrospective cohort study included patients with early-stage (IA) peripheral lung cancer who underwent transbronchial RFA due to inoperability or refusal of surgery from August 2020 to December 2023. All patients underwent transbronchial RFA under the guidance of X-ray or cone-beam computed tomography (CBCT). The safety endpoint included the incidence of adverse events in the month after ablation. The efficacy endpoints involved the local control progression-free survival (LPFS), as well as the factors affecting therapeutic outcomes. RESULTS: A total of 46 patients with 51 tumors underwent 55 transbronchial RFA procedures. The mean age of patients was 67.7 years, and the mean lesion size was 16.4 mm. Adverse events and intervention-acquired adverse events were reported in 11.5% and 9.8% of participants. The local control analysis revealed 1-, 2-, and 3-year LPFS rates of 87.5%, 73.4%, and 69.8%, respectively. The efficacy predictor analysis revealed that transbronchial RFA guided by CBCT had significantly better LPFS compared to that of X-ray guidance (1- and 3-year LPFS rates: 97.2% vs. 55.4% and 79.3% vs. 36.9%, respectively). CONCLUSIONS: Transbronchial RFA for peripheral lung cancer showed a favorable safety profile. The efficacy of transbronchial RFA was also evaluated, and it was found that CBCT-guided bronchial ablation had better outcomes. Future studies will require prospective randomized controlled trials to further confirm its efficacy.